Allison P. Nicklin

• Represented a global pharmaceutical company in the license of a late-stage antibiotic for the treatment of complicated urinary tract infections; transaction includes up to $600 million in milestone payments*
• Represented and pharmaceutical company in connection with its license and collaboration with a neuroscience-focused, biopharmaceutical company in order to develop first-in-class treatments for epilepsy*
• Represented a biotechnology company in a licensing and collaboration agreement for two protein therapy platforms with a leader in RNA-targeting therapeutics*
• Represented biotechnology and pharmaceutical companies in connection with various research, development and collaboration agreements, license agreements, strategic funding transactions, and supply, commercialization and co-promote agreements*
• Represented a global pharmaceutical company in connection with multiple companion diagnostic development, manufacture and supply transactions*

* Denotes experience prior to joining Goodwin

• Represented a cell and gene therapy manufacturer in connection with its $350 million equity financing*
• Represented a regenerative medicine biotechnology company in connection with its $40 million preferred stock financing*
• Represented a cell therapy biotechnology company in connection with its restructuring and $160 million preferred stock financing*
• Represented numerous biotechnology, health care, and specialty pharmaceutical companies in connection with formation, seed, and venture financing, bridge notes and other debt financings and general corporate matters*
• Represented multiple biotechnology startups in connection with sponsored research agreements, option and licensing agreements, and other collaborations with universities and academic institutions*

*Denotes experience prior to joining Goodwin

• Represented a private equity-backed manufacturer of biomaterial coatings for medical devices in its strategic acquisition by a private equity fund*
• Represented a global pharmaceutical company focused on allergy diagnosis and treatment in the sale of its US veterinary business to a Swedish companion-animal allergy testing and treatment company*
• Represented a specialty pharmaceutical company focused on therapeutics for acute care settings in its spin-off from a public contract manufacturing organization and listing on the Nasdaq Capital Market*
• Represented a publicly traded international generic pharmaceutical company in the potential acquisition of a branded pharmaceutical company*
• Represented a global laboratory testing company in the acquisition of an analytical laboratory focused on environmental and agricultural testing*

* Denotes experience prior to joining Goodwin